Related Experiment Videos
The pharmacokinetics of melphalan during intermittent therapy of multiple myeloma
1Department of Internal Medicine, University of Bonn, Federal Republic of Germany.
Abstract:
During intermittent melphalan-prednisone therapy the area under the plasma concentration-time curve of melphalan increased by an average of 45% after oral or intravenous administration of the drug in myeloma patients during the initial three courses at six-week intervals. The rise in melphalan plasma concentrations could not be referred to an alteration in melphalan elimination, metabolism, erythrocyte/plasma partition ratio, or protein binding. A possible explanation could be that covalent binding sites of melphalan were successively saturated during intermittent treatment, resulting in higher drug concentrations during successive courses of therapy.
Insights
Intermittent melphalan-prednisone therapy led to a 45% increase in melphalan plasma concentrations in myeloma patients. This rise may be due to saturation of drug binding sites during successive treatment courses.
Area of Science:
- Pharmacology
- Oncology
- Clinical Pharmacy
Background:
- Melphalan-prednisone is a common chemotherapy regimen for multiple myeloma.
- Understanding drug pharmacokinetics is crucial for optimizing treatment efficacy and safety.
Purpose of the Study:
- To investigate the pharmacokinetic changes of melphalan during intermittent melphalan-prednisone therapy in multiple myeloma patients.
- To identify potential reasons for observed alterations in melphalan plasma concentrations.
Main Methods:
- Prospective study involving multiple myeloma patients undergoing intermittent melphalan-prednisone therapy.
- Measurement of melphalan plasma concentrations over time after oral and intravenous administration during the initial three treatment courses.
- Analysis of potential factors influencing melphalan pharmacokinetics, including elimination, metabolism, and protein binding.
Main Results:
- A significant average increase of 45% in the area under the plasma concentration-time curve (AUC) of melphalan was observed.
- This increase occurred after both oral and intravenous administration during the first three treatment cycles.
- No significant alterations in melphalan elimination, metabolism, erythrocyte/plasma partition ratio, or protein binding were identified as the cause.
Conclusions:
- The observed increase in melphalan plasma concentrations during intermittent therapy is likely not due to altered drug elimination or metabolism.
- A potential explanation involves the saturation of melphalan's covalent binding sites during successive treatment courses.
- This pharmacokinetic alteration may have implications for melphalan-prednisone dosing and treatment monitoring in multiple myeloma.